154 related articles for article (PubMed ID: 16317060)
1. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy.
Oral EA; Javor ED; Ding L; Uzel G; Cochran EK; Young JR; DePaoli AM; Holland SM; Gorden P
J Clin Endocrinol Metab; 2006 Feb; 91(2):621-8. PubMed ID: 16317060
[TBL] [Abstract][Full Text] [Related]
2. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of leptin therapy in the different forms of human lipodystrophy.
Chong AY; Lupsa BC; Cochran EK; Gorden P
Diabetologia; 2010 Jan; 53(1):27-35. PubMed ID: 19727665
[TBL] [Abstract][Full Text] [Related]
4. Leptin-replacement therapy for lipodystrophy.
Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
[TBL] [Abstract][Full Text] [Related]
5. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
Diker-Cohen T; Cochran E; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
[TBL] [Abstract][Full Text] [Related]
7. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
[TBL] [Abstract][Full Text] [Related]
8. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
9. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
[TBL] [Abstract][Full Text] [Related]
10. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
[TBL] [Abstract][Full Text] [Related]
11. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.
Kamran F; Rother KI; Cochran E; Safar Zadeh E; Gorden P; Brown RJ
Horm Res Paediatr; 2012; 78(5-6):320-5. PubMed ID: 22965160
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
[TBL] [Abstract][Full Text] [Related]
13. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
[TBL] [Abstract][Full Text] [Related]
14. Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides.
Joseph J; Shamburek RD; Cochran EK; Gorden P; Brown RJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1676-80. PubMed ID: 24926953
[TBL] [Abstract][Full Text] [Related]
15. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
16. Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis.
Prabhu Anand S; Selvaraj P; Narayanan PR
Cytokine; 2009 Feb; 45(2):105-10. PubMed ID: 19091593
[TBL] [Abstract][Full Text] [Related]
17. Rationale for leptin-replacement therapy for severe lipodystrophy.
Oral EA; Chan JL
Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunity before and after leptin replacement therapy.
Paz-Filho GJ; Delibasi T; Erol HK; Wong ML; Licinio J
J Pediatr Endocrinol Metab; 2009 Nov; 22(11):1069-74. PubMed ID: 20101893
[TBL] [Abstract][Full Text] [Related]
19. Alterations in T-lymphocyte sub-set profiles and cytokine secretion by PBMC of systemic lupus erythematosus patients upon in vitro exposure to organochlorine pesticides.
Dar SA; Das S; Ramachandran VG; Bhattacharya SN; Mustafa MD; Banerjee BD; Verma P
J Immunotoxicol; 2012; 9(1):85-95. PubMed ID: 22214240
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
